A phase II study of trimetrexate therapy for metastatic colorectal carcinoma.

Journal Article

Thirty patients with measurable metastatic colorectal carcinoma who had not received prior systemic therapy for advanced disease were treated with trimetrexate, a methotrexate analog. Trimetrexate was administered at a median daily dose of 15 mg/m2 (range, 6-22 mg/m2) intravenously for five days every three weeks. No patient achieved a complete or partial response, although minor responses of brief duration occurred in eight patients. The drug was generally well tolerated, thus permitting frequent dose escalations. Common toxic effects included mucositis, dermatitis, and myelosuppression. Our data suggest that trimetrexate given at these doses and in this schedule is not active against colorectal carcinoma.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; Abbruzzese, JL; Faintuch, JS; Patt, YZ; Boman, BM; Jackson, DE; Levin, B; Krakoff, IH

Published Date

  • January 1990

Published In

Volume / Issue

  • 8 / 6

Start / End Page

  • 619 - 621

PubMed ID

  • 2149834

Electronic International Standard Serial Number (EISSN)

  • 1532-4192

International Standard Serial Number (ISSN)

  • 0735-7907

Digital Object Identifier (DOI)

  • 10.3109/07357909009018929

Language

  • eng